| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Departments of 1 Nutrition and 2 Statistics, University of Oslo, Oslo, Norway; 3 Institute of Community Medicine, University of Tromsø, Tromsø, Norway; 4 Institute for Preventive Medicine, Nutrition and Cancer, Folkhälsan Research Center and Department of Clinical Chemistry, University of Helsinki, Helsinki, Finland; and 5 Department of Preventive Medicine, University of Southern California, Los Angeles, California
Requests for reprints: Anne Stuedal, Department of Nutrition, University of Oslo, P.O. Box 1046, Blindern, 0316 Oslo, Norway. Phone: 472-285-1334; Fax: 472-285-1532. E-mail: anne.stuedal{at}medisin.uio.no
Aims: Certain phytoestrogens, such as lignans, may protect against developing breast cancer. Enterolactone is a lignan metabolite produced by the intestinal flora from dietary precursors such as whole grains, vegetables, and fruits. Enterolactone has been shown to have weak estrogenic and antiestrogenic properties. We decided to examine the association between plasma levels of enterolactone and mammographic density, a biomarker for breast cancer risk.
Methods: We included data from postmenopausal women ages 55 and older who participated in a cross-sectional mammogram study in Tromsø, Norway. Mammograms, plasma enterolactone measurements, as well as information on anthropometric and hormonal/reproduction factors were available on 616 women. We assessed mammographic density using a previously validated computer-assisted method. We estimated correlation coefficients and conducted multiple regression analyses.
Results: Mean mammographic density increased slightly across quartiles of enterolactone; the women in the highest quartile had, on average, 3.1% (absolute difference) higher percentage mammographic density compared with the lowest quartile (Ptrend < 0.01). After adjustment for age, body mass index, number of full-term pregnancies, age at first birth, and use of postmenopausal hormone therapy, the mean difference in density was reduced to 2.0% (Ptrend = 0.05). Results were similar when restricted to the 454 current hormone nonusers. The fully adjusted statistical model explained 28.3% of the total variability in mammographic percentage density, with body mass index contributing 18.2% and enterolactone only 0.9%.
Conclusion: In our study, higher levels of enterolactone were associated with slightly higher percentage mammographic density. Our results suggest that if higher enterolactone levels reduce the risk of developing breast cancer in postmenopausal women, then this effect is not through lowering mammographic density.
This article has been cited by other articles:
![]() |
B. J. Fuhrman, B. E. Teter, M. Barba, C. Byrne, A. Cavalleri, B. J. Grant, P. J. Horvath, D. Morelli, E. Venturelli, and P. C. Muti Equol Status Modifies the Association of Soy Intake and Mammographic Density in a Sample of Postmenopausal Women Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 33 - 42. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Nagata, T. Matsubara, T. Hara, H. Fujita, Y. Nagao, S. Yamamoto, C. Shibuya, Y. Kashiki, and H. Shimizu Urinary 6-Sulfatoxymelatonin and Mammographic Density in Japanese Women Cancer Epidemiol. Biomarkers Prev., November 1, 2007; 16(11): 2509 - 2512. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Cell Growth & Differentiation |